Last reviewed · How we verify
NCT05274594
Efficacy of Preoperative Radiotherapy for Non-responder Patients After Neoadjuvant Chemotherapy
trial testing Radiotherapy in Breast Neoplasms in 37 participants. Completed in 1 January 2022.
1 January 2020
Quick facts
| Lead sponsor | Istanbul Breast Society |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 1 January 2017 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Radiotherapy — full drug profile →
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Radiotherapy; Complications — all drugs for Radiotherapy; Complications →
- Survivorship — all drugs for Survivorship →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Istanbul Breast Society
Who can join
Adults 18 to 70, female only, with Breast Neoplasms or Radiotherapy; Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neoadjuvant chemotherapy (NACT) is widely used for locally advanced breast cancer cases. As the key factor is to achieve pathologic complete response (pCR), several physicians tried administering radiotherapy before surgery to increase response rates. In this single center observational cohort study, we aim to present the initial results as complete response rates and complication rates of additional neoadjuvant radiotherapy (NART) after NACT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
Montero A, Ciérvide R. · · 2022 · cited 15× · PMID 36547182 · DOI 10.3390/curroncol29120768
Verify or expand the search:
- PubMed search for NCT05274594
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiotherapy
Trials testing the same drug.
- NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
- NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
- NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05274594 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Breast Society
- Last refreshed: 10 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05274594.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing